Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab

Barnett, Richard S.; Barta, Valerie S.; Jhaveri, Kenar D.

doi:10.1056/nejmc1614298

Cited by 125 publications

(77 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 A recent case correspondence suggested that the use of preemptive glucocorticoids might have prevented the onset of rejection in a patient with a kidney transplant who received nivolumab. 20 Given the fulminant and ultimately fatal organ rejection observed in these two patients treated with nivolumab, we strongly advise avoid-…”

Section: Discussionmentioning

confidence: 98%

“…We hypothesize that antibody‐mediated rejection may have been a secondary phenomenon, as T‐cell activation is known to trigger costimulatory ligands and cytokines, resulting in a humoral response . A recent case correspondence suggested that the use of preemptive glucocorticoids might have prevented the onset of rejection in a patient with a kidney transplant who received nivolumab …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma

Friend

Venick

McDiarmid

et al. 2017

Pediatric Blood & Cancer

114

View full text Add to dashboard Cite

Although checkpoint inhibitor therapies have demonstrated significant efficacy in many malignancies, they have not been well studied in patients with a history of solid organ transplant. We describe two patients with recurrent, refractory, and progressive advanced fibrolamellar hepatocellular carcinoma (HCC) following orthotopic liver transplantation who received programmed cell death protein 1 (PD-1) inhibitor, nivolumab, on a patient access, off-label basis. Both rapidly developed irreversible acute liver rejection shortly after starting therapy, and ultimately died. While checkpoint inhibitors clearly have tremendous potential as a targeted therapy, they should be avoided or used with extreme caution in the context of an organ transplant.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma

Friend

Venick

McDiarmid

et al. 2017

Pediatric Blood & Cancer

114

View full text Add to dashboard Cite

show abstract

“…Accounts of these cases, which at present amount to less than 40 published reports, confirm that organ rejection is a frequent occurrence in this setting. [6][7][8] However, good tolerability and signs of significant anticancer efficacy were observed in some cases. 6 As of today, to our knowledge 14 cases of liver transplant recipients who have been treated with immune CPIs have been published (Table 1).…”

mentioning

confidence: 99%

Use of checkpoint inhibitors in liver transplant recipients

Munker

Toni

2018

UEG Journal

View full text Add to dashboard Cite

In spite of their major impact in cancer therapy, immune checkpoint inhibitors are considered to be contraindicated in liver transplant recipients due to fear of rejection and fatal liver failure. Nevertheless, an increasing number of instances of liver transplant recipients treated with checkpoint inhibitors is being published. We reviewed the reports on 14 known cases of liver transplant recipients who underwent treatment with checkpoint inhibitors and discuss factors likely to determine susceptibility to organ rejection including the choice of the agent and the immunosuppression employed, the assessment of Programmed cell death 1 ligand 1 (PD-L1) status in liver graft biopsies, and the time of treatment initiation.

show abstract

“…The latter was reported in two cases of patients undergone to renal transplantation. Barnett, Barta and Jhaveri (2017) showed the allograft prevention in a patient treated with nivolumab with an immunosuppressive regimen consisting of sirolimus and prednisone. Most of the reported cases (Table 1) showed good tolerance to the drug without serious adverse events.…”

Section: Discussionmentioning

confidence: 99%

“…Relevant factors that increase the risk of death for this tumor include (a) diameter exceeding 20 mm, (b) poor differentiation, (c) location on special areas (i.e., lip, ear or temple), (d) perineural invasion, and (e) immunosuppression (Stratigos et al, ). Nowadays, there are no therapies approved by U.S. Food and Drug Administration (FDA) for advanced stages, and the combination of chemotherapy and radiotherapy did not improve conspicuously the prognosis (Behshad, Garcia‐Zuazaga, & Bordeaux, ). Historically, the most frequent treatments included 5‐fluorouracil, cisplatin, carboplatin, or paclitaxel, alone or in combination (Martinez, Otley, Okuno, Foote, & Kasperbauer, ).…”

Section: Introductionmentioning

confidence: 99%

Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death‐1 inhibitors: A review of the literature

Corneli

Conforti

Retrosi

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Cutaneous squamous cell carcinoma (cSCC) is the second most frequent nonmelanoma skin cancer (NMSC). The majority of in situ cSCC [cSCC (Tis)] can be cured surgically, while local advanced and metastatic ones require other treatments, but there are no therapies approved by U.S. Food and Drug Administration (FDA). Available treatments for these stages included radiotherapy, chemotherapy as cisplatin, but responses to these treatments are usually of short duration. Programmed death‐1 (PD‐1) inhibitors (pembrolizumab, nivolumab, and cemiplimab) are an innovative immunologic treatment that now has been shown to be useful for the treatment of advanced cSCC. Nowadays, data about the response rate with the use of PD‐1 inhibitors in cSCC are still few and, especially, the duration of the response after the start of treatment is short. Moreover, the number of cases is too small to express the beneficial effects of these treatments, although most data reported in the literature show quite good response rates. This review focused on some of the studies and associated results through an interesting research on search engines of all the cases about these systemic drugs, analyzing effects and side effects, and the research has been conducted considering published cases since March 2016 to October 2019.

show abstract

Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab

Cited by 125 publications

References 5 publications

Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma

Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma

Use of checkpoint inhibitors in liver transplant recipients

Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death‐1 inhibitors: A review of the literature

Contact Info

Product

Resources

About